Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation.

Chronic blockade of dopamine D2 receptors, a common mechanism of action for antipsychotic drugs, down-regulates D1 receptors in the prefrontal cortex and, as shown here, produces severe impairments in working memory. These deficits were reversed in monkeys by short-term coadministration of a D1 agonist, ABT 431, and this improvement was sustained for more than a year after cessation of D1 treatment. These findings indicate that pharmacological modulation of the D1 signaling pathway can produce long-lasting changes in functional circuits underlying working memory. Resetting this pathway by brief exposure to the agonist may provide a valuable strategy for therapeutic intervention in schizophrenia and other dopamine dysfunctional states.

[1]  Bryan Kolb,et al.  Alterations in the morphology of dendrites and dendritic spines in the nucleus accumbens and prefrontal cortex following repeated treatment with amphetamine or cocaine , 1999, The European journal of neuroscience.

[2]  T Suhara,et al.  Possible role of dopamine D1 receptors in schizophrenia , 1997, Molecular Psychiatry.

[3]  P. Goldman-Rakic,et al.  Down-regulation of the D1 and D5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs. , 1997, The Journal of pharmacology and experimental therapeutics.

[4]  J. Schneider,et al.  Effects of dihydrexidine, a full dopamine D-1 receptor agonist, on delayed response performance in chronic low dose MPTP-treated monkeys , 1994, Brain Research.

[5]  P. Goldman-Rakic,et al.  Modulation of memory fields by dopamine Dl receptors in prefrontal cortex , 1995, Nature.

[6]  I. Creese,et al.  Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs. , 1997, The Journal of pharmacology and experimental therapeutics.

[7]  P. Goldman-Rakic,et al.  The anatomy of dopamine in monkey and human prefrontal cortex. , 1992, Journal of neural transmission. Supplementum.

[8]  G. Vauquelin,et al.  The effect of aging on the D1 dopamine receptors in human frontal cortex , 1990, Brain Research.

[9]  M. O’Donovan,et al.  Both splicing variants of the dopamine D2 receptor mRNA are up-regulated by antipsychotic drugs , 1993, Neuroscience Letters.

[10]  P. Seeman,et al.  Dopamine receptors and the dopamine hypothesis of schizophrenia , 1987, Synapse.

[11]  D. Price,et al.  Age-related changes in multiple neurotransmitter systems in the monkey brain , 1989, Neurobiology of Aging.

[12]  M. Levine,et al.  Effects of repeated amphetamine treatment on the locomotor activity of the dopamine D1A‐deficient mouse , 1997, Neuroreport.

[13]  H. Meltzer,et al.  The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. , 1999, Schizophrenia bulletin.

[14]  M. Iyo,et al.  Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET , 1997, Nature.

[15]  Effects of the D-1 agonist SKF-38393 combined with haloperidol in schizophrenic patients. , 1990 .

[16]  C. Tamminga,et al.  The Effect of Chronic Haloperidol Treatment on Dendritic Spines in the Rat Striatum , 1997, Experimental Neurology.

[17]  P. Goldman-Rakic,et al.  Noise stress impairs prefrontal cortical cognitive function in monkeys: evidence for a hyperdopaminergic mechanism. , 1998, Archives of general psychiatry.

[18]  P. Goldman-Rakic,et al.  The cerebral cortex: a case for a common site of action of antipsychotics. , 1998, Trends in pharmacological sciences.

[19]  P. Vezina,et al.  Microinjections of Sch-23390 into the ventral tegmental area and substantia nigra pars reticulata attenuate the development of sensitization to the locomotor activating effects of systematic amphetamine , 1989, Brain Research.

[20]  M. Mishkin,et al.  An early and a late developing system for learning and retention in infant monkeys. , 1984, Behavioral neuroscience.

[21]  P. Kalivas,et al.  Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity , 1991, Brain Research Reviews.

[22]  T. Robinson,et al.  Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosis , 1986, Brain Research Reviews.

[23]  T. Chase,et al.  Dopamine D1 receptor stimulation but not dopamine D2 receptor stimulation attenuates haloperidol-induced behavioral supersensitivity and receptor up-regulation. , 1993, European journal of pharmacology.

[24]  P. Goldman-Rakic,et al.  D1 dopamine receptors in prefrontal cortex: involvement in working memory , 1991, Science.

[25]  J. Goss,et al.  Haloperidol treatment increases D2 dopamine receptor protein independently of RNA levels in mice. , 1991, Life sciences.

[26]  P. Goldman-Rakic,et al.  A common action of clozapine, haloperidol, and remoxipride on D1- and D2-dopaminergic receptors in the primate cerebral cortex. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[27]  P. Vezina,et al.  D1 dopamine receptor activation is necessary for the induction of sensitization by amphetamine in the ventral tegmental area , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[28]  P. Goldman-Rakic,et al.  Distribution of dopaminergic receptors in the primate cerebral cortex: Quantitative autoradiographic analysis using [3H]raclopride, [3H]spiperone and [3H]SCH23390 , 1991, Neuroscience.

[29]  G. Breese,et al.  Priming of D1-dopamine receptor responses: long-lasting behavioral supersensitivity to a D1-dopamine agonist following repeated administration to neonatal 6-OHDA-lesioned rats , 1989, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[30]  C. Oberlander,et al.  The kappa opioid agonist niravoline decreases brain edema in the mouse middle cerebral artery occlusion model of stroke. , 1997, The Journal of pharmacology and experimental therapeutics.

[31]  M. Le Moal,et al.  Evidence for selective involvement of dopamine D1 receptors of the ventral tegmental area in the behavioral sensitization induced by intra-ventral tegmental area injections of D-amphetamine. , 1996, The Journal of pharmacology and experimental therapeutics.

[32]  Päivi Marjamäki,et al.  Age-dependent decline in human brain dopamine D1 and D2 receptors , 1990, Brain Research.

[33]  F. Benes,et al.  Evidence for ultrastructural changes in cortical axodendritic synapses following long-term treatment with haloperidol or clozapine. , 1991, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[34]  G. Sedvall,et al.  Chemical brain anatomy in schizophrenia , 1995, The Lancet.